Evaluating the cost of managing patients with cellulitis in Wales, UK: A 20‐year population‐scale study

• Published in: International wound journal 2023-08, Vol.20 (6), p.2129-2140
• Main Authors: Humphreys, Ioan, Akbari, Ashley, Griffiths, Rowena, Graham‐Woollard, Dave, Morgan, Karen, Noble‐Jones, Rhian, Gabe‐Walters, Marie, Thomas, Melanie
• Format: Article
• Language: English
• Subjects: Age groups; Antibiotics; Cellulitis; Cellulitis - therapy; Codes; Cost control; Cost-Benefit Analysis; Costs and Cost Analysis; economic burden; Health services; Humans; longitudinal data; Lymphedema; lymphoedema; Missing data; Original; Patient admissions; Primary care; Quality control; Risk factors; SAIL databank; State Medicine; Statistical analysis; Survival analysis; Wales
• ISSN: 1742-4801; 1742-481X
• DOI: 10.1111/iwj.14088

This study aimed to estimate costs associated with managing patients with cellulitis from the UK National Health Service (NHS) perspective. The analysis was undertaken through the Secure Anonymised Information Linkage Databank, which brings together population‐scale, individual‐level anonymised linked data from a wide range of sources, including 80% of primary care general practices within Wales (population coverage ~3.2 million). The data covered a 20‐year period from 1999 to 2019. All patients linked to the relevant codes were tracked through primary care settings, recording the number of general practice visits (number of days with an event recorded) and number of in‐patient stays. Resources were valued in monetary terms (£ sterling), with costs determined from national published sources of unit costs. These resources were then extrapolated out to reflect UK NHS costs. This is the first attempt to estimate the financial burden of cellulitis using routine data sources on a national scale. The estimated direct annual costs to the Welsh NHS (£28 554 338) are considerable. In‐Patient events and length of stay costs are the main cost drivers, with annual Welsh NHS estimates of £19 664 126 with primary care events costing £8 890 212. Initiatives to support patients and healthcare professionals in identifying early signs/risks of cellulitis, improve the accuracy of initial diagnosis, prevent cellulitis recurrence, and improve evidence‐based treatment pathways would result in major financial savings, to both the Welsh and UK NHS. In light of these findings, Wales has developed the innovative National Lymphoedema cellulitis Improvement Programme to address these burdens; providing a proactive model of cellulitis care.